duramycin and Lymphoma--Large-B-Cell--Diffuse

duramycin has been researched along with Lymphoma--Large-B-Cell--Diffuse* in 1 studies

Other Studies

1 other study(ies) available for duramycin and Lymphoma--Large-B-Cell--Diffuse

ArticleYear
Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report.
    Clinical nuclear medicine, 2023, Jan-01, Volume: 48, Issue:1

    Duramycin, a 19 amino acids peptide, is known for its potential to target phosphatidylethanolamine. During cell death (apoptosis), rearrangement of membrane phospholipids results in the externalization of phosphatidylethanolamine to the outer leaflet of the cell membrane, which can be imaged using 68Ga-NOTA-duramycin. We report 68Ga-NOTA-duramycin imaging in a 50-year-old man with biopsy-proven diffuse large B-cell lymphoma planned for anthracycline-based chemotherapy. 68Ga-NOTA-duramycin PET/CT imaging along with 18F-FDG PET/CT was performed before and after 2 cycles of chemotherapy. The tracer avidity in interim 68Ga-NOTA-duramycin PET/CT showed its diagnostic potential to assess early response to chemotherapy.

    Topics: Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Peptides; Phosphatidylethanolamines; Positron Emission Tomography Computed Tomography

2023